Table S1. Summary of sensitive analysis for prophylaxis efficacy. Figure S1. Source of bias in two randomized trials following Cochrane Collaborationâs tool. Figure S2. Sensitive analysis of individual study involved at cut-off value of 0.5Â mg/L (A) and 0.7Â mg/L (B). Statement for detailed searching strategy. (PDF 301 kb
Table S1. Study search strategy. Table S2. Information on excluded studies. Table S3. List of Ongoin...
Change from baseline in maximum voluntary ventilation (MVV). Mean changes from baseline to week 72 i...
The funnel plots for the tolerability, neurotoxicity, visual toxicity, hepatotoxicity, and nephrotox...
Figure S1. Assessment of risk of bias in included trials. Figure S2. Forrest plot based on aggregate...
A summary of sensitive analysis for voriconazole safety after excluding a group of studies which was...
Table S1. Characteristics of the studies included in the meta-analysis. Table S2. Quality of assessm...
Table S1. Sample search strategy for MEDLINE. Table S2. The reason for excluding studies. Table S3. ...
Table S2. Risk of bias assessment according to the modified Cochrane Collaboration tool for randomiz...
Supplementary Methods. Figure S1. Flow chart showing the process of study selection and numbers of s...
Item does not contain fulltextBACKGROUND: Posaconazole is indicated for prophylaxis and salvage ther...
Table S1. Quality assessment for randomized controlled trials by Cochrane risk evaluation tool. Tabl...
Forest plots of odds ratios for second outcomes (see in Figure S1-S8). (DOCX 11351 kb
Table S1. MEDLINE search strategy. Table S2. EMBASE search strategy. Table S3. SCOPUS search strateg...
Table S1. Study characteristics: management description of included randomized controlled trials. Ta...
Additional file 1: Table A1. Search terms. Fig. A1. Study selection flowchart of randomized controll...
Table S1. Study search strategy. Table S2. Information on excluded studies. Table S3. List of Ongoin...
Change from baseline in maximum voluntary ventilation (MVV). Mean changes from baseline to week 72 i...
The funnel plots for the tolerability, neurotoxicity, visual toxicity, hepatotoxicity, and nephrotox...
Figure S1. Assessment of risk of bias in included trials. Figure S2. Forrest plot based on aggregate...
A summary of sensitive analysis for voriconazole safety after excluding a group of studies which was...
Table S1. Characteristics of the studies included in the meta-analysis. Table S2. Quality of assessm...
Table S1. Sample search strategy for MEDLINE. Table S2. The reason for excluding studies. Table S3. ...
Table S2. Risk of bias assessment according to the modified Cochrane Collaboration tool for randomiz...
Supplementary Methods. Figure S1. Flow chart showing the process of study selection and numbers of s...
Item does not contain fulltextBACKGROUND: Posaconazole is indicated for prophylaxis and salvage ther...
Table S1. Quality assessment for randomized controlled trials by Cochrane risk evaluation tool. Tabl...
Forest plots of odds ratios for second outcomes (see in Figure S1-S8). (DOCX 11351 kb
Table S1. MEDLINE search strategy. Table S2. EMBASE search strategy. Table S3. SCOPUS search strateg...
Table S1. Study characteristics: management description of included randomized controlled trials. Ta...
Additional file 1: Table A1. Search terms. Fig. A1. Study selection flowchart of randomized controll...
Table S1. Study search strategy. Table S2. Information on excluded studies. Table S3. List of Ongoin...
Change from baseline in maximum voluntary ventilation (MVV). Mean changes from baseline to week 72 i...
The funnel plots for the tolerability, neurotoxicity, visual toxicity, hepatotoxicity, and nephrotox...